In a recent Benefits Pro article What employers need to know about "guided use" of cannabis by Dr. Brooke Worster, an Associate Professor of Medicine at Jefferson Health in Philadelphia, PA, the Director of the Division of Supportive Oncology, and the Program Director of Cannabis Medicine for the Science and Business Master’s Program, she explores the evolving dynamics of employee cannabis use, as well as implications, and opportunities to provide guidance on when, where, and what cannabis use is acceptable.
In a rapidly changing landscape where cannabis is now legal in most states, the need for informed guidance for employers and employees is paramount. The role of employers in ensuring safe, guided cannabis use is becoming increasingly important.
Medical experts advocate for the potential benefits of cannabis in treating various medical conditions. Boasting a massive $33 billion in sales, $10 billion of which is directed towards health-related usage, cannabis is proving its place in modern health practices. As Gen Z and Millennials embrace this trend, employers face a crucial crossroads about providing guidance on safe cannabis consumption which remains largely uncharted territory in a landscape where clinical guidance is often lacking. More than ever, employers need to adapt their policies to support employees who may choose cannabis as part of their healthcare journey.
As the leader in cannabinoid based symptom management for older adults, we applaud the Centers for Medicare & Medicaid Services (CMS) proposal to expand coverage for federally legal, hemp-derived cannabinoid-based products. At EO, we are uniquely positioned to meet the need of this new, covered cannabinoid care market.
At EO, we systematically track how patients feel and function after starting guided cannabis care. The data below come from real people using cannabis to manage symptoms such as pain, sleep disturbance, anxiety, and nausea/vomiting, under the guidance of our clinical protocols.
Meaningful improvements were reported by patients after one (1) week and sustained through four (4) weeks of guided cannabinoid care, particularly among people over 50 and cancer patients. Patients also reported low rates of use-limiting side effects with further reductions after receiving updated recommended product and/or dosing guidance via EO Care’s digital care platform.
Get special offers, event invites and the latest on new care offerings and product releases.
Wise Use for All
© 2025 All rights reserved. Patents pending. EO Care, Inc.
